Relmada Therapeutics, Inc.
General ticker "RLMD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $29.0M (TTM average)
Relmada Therapeutics, Inc. follows the US Stock Market performance with the rate: 44.9%.
Estimated limits based on current volatility of 3.5%: low 6.92$, high 7.42$
Factors to consider:
- Total employees count: 20 (+42.9%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Dependence on product approval, Operational and conduct risks, Labor/talent shortage/retention, Strategic risks and growth management, Cybersecurity threats
- Current price 41.4% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.77$, 5.29$]
- 2026-12-31 to 2027-12-31 estimated range: [1.25$, 3.71$]
Financial Metrics affecting the RLMD estimates:
- Positive: with PPE of -3.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -26.11 <= 0.07
- Negative: negative Net income
- Negative: Investing cash flow per share per price, % of -27.46 <= -14.24
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
Short-term RLMD quotes
Long-term RLMD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $103.70MM | $83.89MM | $59.10MM |
| Operating Income | $-103.70MM | $-83.89MM | $-59.10MM |
| Non-Operating Income | $4.91MM | $3.91MM | $1.72MM |
| R&D Expense | $54.81MM | $46.18MM | $0.74MM |
| Income(Loss) | $-98.79MM | $-79.98MM | $-57.39MM |
| Profit(Loss)* | $-98.79MM | $-79.98MM | $-114.77MM |
| Stockholders Equity | $85.36MM | $35.52MM | $86.51MM |
| Assets | $97.55MM | $45.82MM | $94.00MM |
| Operating Cash Flow | $-51.66MM | $-51.76MM | $-45.79MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $50.45MM | $51.56MM | $-48.14MM |
| Financing Cash Flow | $-0.10MM | $-0.04MM | $93.56MM |
| Earnings Per Share** | $-3.28 | $-2.65 | $-2.91 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.